Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Indian IP Bill Would Give Drug Inventor, Institution Shares Of Patent Profits

This article was originally published in PharmAsia News

Executive Summary

Pharmaceutical scientists and others are expected to benefit as well as the institutions they work for under a bill under review by the Indian government. A draft of the intellectual property measure proposes a system similar to that of the United States, which allows public institutions to patent inventions and enter into commercial ventures to market the work. The proposal, which India's Cabinet is to decide whether to introduce in Parliament, would have the inventor of the patentable product to receive 30 percent of market revenue, with 10 percent allocated to the institution where the work was produced. (Click here for more

You may also be interested in...



Filgotinib On Uncertain Path As Gilead Regains Speed From Pandemic Hit

Third quarter earnings show Gilead’s Immunomedics buy paid off, but filgotinib’s path may narrow. The HIV and HCV franchises picked up from their COVID-19 lull.

FDA’s Final MOU On Interstate Compounding Now Awaits Signatures From States

US pharmacy group says that 10 to 12 states have indicated through an informal survey that they do not have the manpower or funding to implement the US FDA’s final MOU on inordinate compounding. They say what is at stake in these states is patient access to compounded medicines.

Google Teams Up With Mayo Clinic To Explore AI To Improve Radiotherapy Planning

Mayo Clinic announces AI-based partnerships with Google and voice-analysis company Vocalis Health this week.

UsernamePublicRestriction

Register

LL1134446

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel